NCT03930953 2026-02-19A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)CelgenePhase 1/2 Active not recruiting438 enrolled
NCT04680052 2025-12-22InMINDIncyte CorporationPhase 3 Active not recruiting654 enrolled 40 charts 3 FDA